Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

This study has been withdrawn prior to enrollment.
Information provided by:
AstraZeneca Identifier:
First received: November 9, 2010
Last updated: June 6, 2011
Last verified: June 2011

The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance

Self-administered Questionnaire to Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • low-dose aspirin and gastroprotective treatment compliance (Girerd questionnaire: a 6-item self-administered and validated questionnaire to evaluate adherence to treatments) [ Time Frame: One month ] [ Designated as safety issue: No ]

Estimated Enrollment: 7300
Study Start Date: June 2011
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Community sample


Inclusion Criteria:

  • French people > 60 years old, part of Kantar Health Access Sant� panel

Exclusion Criteria: -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01238809

Sponsors and Collaborators
Principal Investigator: Mrs Genevieve BONNELYE KantarHealth - France
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Identifier: NCT01238809     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2010/1
Study First Received: November 9, 2010
Last Updated: June 6, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
France processed this record on November 24, 2014